Impaired efferocytosis by monocytes and monocyte-derived macrophages in patients with poorly controlled type 2 diabetes

Table 1 Clinical characteristics of type 2 diabetes or healthy control

		Control subjects (n = 30)	Type 2 diabetes (n = 30)	P value
	Sex (F/M)	9/21	9/21	/
	Age (years)	50 ± 10	50 ±10	0.925
	Waist-to-hip ratio	0.90 ± 0.09	0.98 ± 0.04	0.010
	BMI (kg/m2)	22.83 ± 2.41	25.37 ± 4.14	0.016
	Systolic blood pressure (mmHg)	129 ± 12	132 ± 16	0.441
	Diastolic blood pressure (mmHg)	77 ± 10	80±10	0.221
	Mean arterial blood pressure (mmHg)	95.2 ± 9.7	97.6 ± 10.4	0.340
Glucose metabolism factors	Fasting plasma glucose (mmol/L)	5.07 ± 0.42	11.36 ± 0.43	< 0.001
	HbA1c (%)	5.1± 0.4	11.6 ± 2.3	< 0.001
	HbA1c (mmol/mol)	32 ± 4	104 ± 25	< 0.001
Lipid metabolism factors	Total cholesterol (mmol/L)	4.21 ± 0.77	4.78 ± 1.39	0.043
	Triglycerides (mmol/L)	1.44 ± 0.76	2.04 ± 1.94	0.077
	HDL cholesterol (mmol/L)	1.14 ± 0.26	1.38 ± 1.56	0.426
	LDL cholesterol (mmol/L)	2.77 ± 0.93	2.64 ± 0.89	0.483
	Apolipoprotein A (mmol/L)	1.23 ± 0.23	1.13 ± 0.31	0.419
	Apolipoprotein B (mmol/L)	0.89 (0.29)	0.97 (0.38)	0.294
	ApoA/ApoB ratio	1.43 (0.55)	1.18 (0.64)	0.110
Bone metabolism parameters	B-CTX (ng/mL)	0.49 (0.41)	0.45 (0.36)	0.053
	P1NP (ng/mL)	57.48 (28.55)	31.98 (21.56)	0.003
	Osteocalcin (ng/mL)	16.84 (6.36)	10.45 (6.03)	< 0.001
	25(OH)D (nmol/L)	50.59 ± 20.70	45.79 ± 20.73	0.605
	PTH (pmol/L)	3.86 (1.78)	3.15 (2.20)	0.079
Inflammatory factors	hsCRP (mg/L)	0.50 (1.50)	2.00 (4.00)	0.011
	TNF-α (pg/mL)	1.00 (1.08)	0.83 (0.91)	0.575
	IL-1β (pg/mL)	0.17 (0.95)	0.66 (1.61)	0.031
	IL-6 (pg/mL)	2.25 (3.27)	3.11 (2.18)	0.149
	IL-8 (pg/mL)	5.37 (5.05)	8.82 (11.90)	0.063
	IL-12 (pg/mL)	1.14 (1.38)	1.24 (1.03)	0.881
	IL-10 (pg/mlL)	0.22 (0.97)	0.24 (0.72)	0.360

Data are mean ± SD, n (%), or median (IQR). P values indicate differences between type 2 diabetes patients (n = 30) and healthy control (n = 30). HbA1c: Glycosylated hemoglobin; BMI: Body mass index; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; hsCRP: Hypersensitive C-reactive protein.